Analyst Update: Open Text Corp, T-Mobile, and Pfizer

Analysts adjusted their ratings on Open Text Corporation (USA) (NASDAQ:OTEX), T-Mobile US Inc (NYSE:TMUS), and Pfizer Inc. (NYSE:PFE)

by Alex Eppstein

Published on May 21, 2015 at 12:14 PM
Updated on Jun 29, 2020 at 3:25 PM

Analysts are weighing in today on software firm Open Text Corporation (USA) (NASDAQ:OTEX), telecom titan T-Mobile US Inc (NYSE:TMUS), and blue chip Pfizer Inc. (NYSE:PFE). Here's a quick roundup of today's brokerage notes on OTEX, TMUS, and PFE.

  • OTEX is fresh off an annual low of $42.29, as the company's strategic update last night -- which included lackluster guidance and a planned 5% workforce reduction -- failed to impress. Brokerage firms panned the presentation, with no fewer than 10 cutting their price targets on Open Text Corporation. At last check, the shares were perched nearly 12% lower at $43.19. Should this technical trajectory persist, additional price-target cuts could come down the pike. OTEX's average 12-month price target is $72.82 -- a 69% premium to current trading levels, and in all-time-high territory.

  • On the flip side, TMUS hit a multi-year high of $36.81 earlier, after the CEO of parent company Deutsche Telekom vowed to consider partners to improve the subsidiary's performance, and also added that it is in a better condition now than two years ago. Subsequently, Bernstein upped its price target on T-Mobile US Inc to $36 from $32 -- still a discount to the stock's current price of $36.36. Put buyers may be wringing their hands amid the equity's 3.3% rally. TMUS sports a 10-day put/call volume ratio of 7.31 across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). Not only does this ratio indicate more than seven puts have been bought to open for every call during the last two weeks, it likewise stands in the 93rd percentile of its annual range.

  • PFE is up 0.3% at $34.41, after being named a "top global pick" by Jefferies. The shares have performed well in 2015, cruising atop their 20-week moving average for a 10.5% year-to-date gain. It also appears Pfizer Inc.'s 10- and 20-day moving averages are on the verge of a bullish cross, suggesting potential upside ahead. Options traders at the ISE, CBOE, and PHLX have been betting bullishly on PFE of late. The stock's 10-day call/put volume ratio checks in at 5.25 -- higher than four-fifths of comparable readings from the past 12 months.

A Schaeffer's 39th Anniversary Exclusive!

8 Top Stock Picks for 2020

Access your FREE insider report before it's too late!


  
 
 

Partnercenter